NCT04855929

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

ANV419 First in Human Study Phase 1: Open-label, Dose Escalation Study of ANV419 As Single Agent and in Combination with Ipilimumab in Patients with Relapsed/Refractory Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: Anaveon AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.

Detailed description

The purpose of this First-in-Human, open-label, dose escalation study is to assess the initial safety and efficacy profile of ANV419 intravenous infusion alone and in combination with ipilimumab in patients with advanced solid tumours. It will evaluate the safety and tolerability of ANV419 alone and in combination with ipilimumab and, the safest and best dose of ANV419 when used alone or in combination.

Conditions

• Advanced Solid Tumor
• Adult Disease
• Lung Cancer

Interventions

Type	Name	Description
DRUG	ANV419	ANV419 administered by intravenous (IV) infusion
DRUG	Ipilimumab	Ipilimumab administered by intravenous (IV) infusion

Timeline

• Start date: 2021-05-25
• Primary completion: 2024-07-18
• Completion: 2024-07-18
• First posted: 2021-04-22
• Last updated: 2024-11-08

Locations

5 sites across 3 countries: Spain, Switzerland, United Kingdom